Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $15.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 185.71% from the stock’s previous close.

Several other research firms have also recently weighed in on COYA. Lake Street Capital restated a “buy” rating and issued a $17.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Friday, November 14th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a research note on Monday, November 24th. Finally, BTIG Research raised their price target on Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $5.25 on Monday. Coya Therapeutics has a 52-week low of $4.65 and a 52-week high of $8.29. The company has a market capitalization of $109.83 million, a PE ratio of -4.73 and a beta of 0.25. The business’s fifty day moving average is $5.89 and its 200 day moving average is $6.06.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $3.70 million. On average, sell-side analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of COYA. CM Management LLC grew its position in Coya Therapeutics by 50.0% during the 3rd quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $1,710,000 after acquiring an additional 100,000 shares during the last quarter. Dauntless Investment Group LLC boosted its stake in shares of Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after purchasing an additional 101,932 shares during the period. Citadel Advisors LLC grew its holdings in shares of Coya Therapeutics by 51.3% in the third quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after purchasing an additional 22,120 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after buying an additional 13,176 shares during the period. Finally, Prosperity Wealth Management Inc. raised its holdings in Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after buying an additional 3,350 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.